Want to see AU:CGS full AI Analyst Report?
CGS Stock Chart & Stats
AU$3.06
-AU$0.05(-1.98%)
At close: 4:00 PM EDT
AU$3.06
-AU$0.05(-1.98%)
Day’s Range― - ―
52-Week RangeAU$1.75 - AU$3.50
Previous CloseN/A
Volume167.93K
Average Volume (3M)363.65K
Market Cap
AU$593.84M
Enterprise ValueAU$434.77M
Total Cash (Recent Filing)AU$34.77M
Total Debt (Recent Filing)AU$359.02K
Price to Earnings (P/E)34.7
Beta0.04
Next Earnings
Feb 24, 2027EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield1.74%
Share Statistics
EPS (TTM)0.07
Shares Outstanding172,126,420
10 Day Avg. Volume326,686
30 Day Avg. Volume363,652
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)8.01
Price to Sales (P/S)7.79
P/FCF Ratio50.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.89Price Target Upside26.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.09
Revenue Forecast (FY)AU$75.80M
Bulls Say, Bears Say
Bulls Say
Contracted Revenue VisibilityThe expanded contracted revenue base improves forward visibility and supports continued growth beyond a single reporting period. With $48.3M expected for FY’27 and additional year-two and year-three revenue locked in, Cogstate has a stronger foundation for planning capacity and investment.
Conservative Balance SheetMinimal debt and a growing equity base reduce financial risk while preserving flexibility to fund technology investment, support operations, and return capital. This conservative structure also gives Cogstate greater resilience if trial timing or customer spending becomes less predictable.
Diversified Clinical GrowthGrowth beyond Alzheimer’s broadens Cogstate’s addressable market and reduces reliance on one therapeutic area. Strong expansion in mood, sleep and other neurological indications, alongside increased rare-disease activity, supports a more diversified and durable clinical-trial pipeline.
Bears Say
Margin Pressure From InvestmentThe lower gross margin shows that growth is currently requiring additional capability investment, which can limit near-term earnings conversion. Although second-half margins improved, sustained profitability will depend on whether the new investments generate sufficient delivery efficiency and operating leverage.
Contract Conversion LumpinessA sizable contracted pipeline does not eliminate timing risk because revenue recognition depends on execution and conversion during the year. Uneven delivery could make reported growth and cash generation less predictable, complicating resource planning and creating variability in operating results.
Maturing Channel DependenceIncreasing partner-sourced sales can extend market reach, but reliance on a still-maturing channel model adds execution and concentration risk. Cogstate’s durable growth profile will depend on sustaining partner productivity while retaining sufficient control over pipeline development and customer conversion.
Cogstate Ltd News
CGS FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest share price was AU$1.75 and its highest was AU$3.50 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is AU$593.84M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Feb 24, 2027 which is in 135 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Aug 17, 2026. The company reported AU$0.06 earnings per share for the quarter, beating the consensus estimate of AU$0.054 by AU$0.006.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Annually dividend of AU$0.04 which represents an annual dividend yield of 1.74%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.06.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 172,126,420 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of AU$0.06 in its last earnings report, beating expectations of AU$0.054. Following the earnings report the stock price went down -2.143%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in AU:CGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.89 (26.96% Upside)
AU$3.89 (26.96% Upside)
Blogger Sentiment
Bullish
AU:CGS Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.47%
12-Months-Change
Fundamentals
Return on Equity
21.61%
Trailing 12-Months
Asset Growth
20.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cogstate Ltd
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
CGS Company Deck
CGS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong, diversified top-line growth, record sales and a materially expanded contracted revenue base, backed by improving second-half margins and completed AI products—positioning the business for continued growth. Management acknowledged near-term margin pressure from purposeful capability investments, conversion timing risk for contracted revenue, a small FX tailwind that may not recur, and dependence on nascent channel partnerships. On balance, the positive operational momentum, robust pipeline and clear technology roadmap outweigh the manageable short-term risks.View all AU:CGS earnings summariesCGS Stock 12 Month Forecast
Average Price Target
AU$3.89
▲(26.96% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―